 |
|
|
|
 |
|
|
| Article 1 to 10 out of 38 concerning Amgen Inc.
|
-
U3 Pharma achieves preclinical proof of concept for U3-1287 (AMG 888)
(04/15/2008)
HER3 antibody a promising novel first-in-class HER family inhibitor
U3 Pharma announced that preclinical proof-of-concept has been established for its lead product U3-1287 (AMG 888), the first fully human anti-HER3 monoclonal antibody (mAb). In vitro and in vivo studies of U3-1287 (AMG 888), which is being developed ...
-
Predictive genetic test for bowel cancer treatment is introduced in the UK
(03/20/2008)
Amgen and Lab21 in Partnership Agreement for New Cancer Therapy Test
Amgen Limited UK and Lab21 have announced their partnership to introduce a new genetic therapy test for advanced bowel cancer treatment in the UK. Under the terms of the agreement, Lab21 will provide a screening test to indicate which patients are ...
-
Amgen Completes Acquisition of Alantos
(07/19/2007)
Amgen announced the completion of its acquisition of Alantos, a private company developing drugs for the treatment of diabetes and inflammatory diseases. The transaction provides Amgen with Alantos's DPP-IV inhibitor in clinical development (Phase ...
-
Amgen to Acquire Ilypsa
(06/06/2007)
Amgen announced that it has agreed to acquire Ilypsa, a private company developing non-absorbed drugs for renal disorders. Ilypsa's lead drug candidate, ILY101, is a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease ...
-
Amgen Names Robert Bradway Executive Vice President and Chief Financial Officer
(04/12/2007)
Amgen announced the appointment of Robert Bradway as executive vice president and chief financial officer. He will be responsible for Amgen's finance, strategy and investor relations operations. Bradway replaces Richard Nanula, who is leaving the ...
-
Graffinity and Amgen enter into drug discovery research agreement
(02/28/2007)
Graffinity Pharmaceuticals GmbH announced that it has entered into a research collaboration with Amgen. Under the terms of the agreement, Graffinity will receive technology access fees and success payments for the generation of novel small molecule ...
-
Cytokinetics and Amgen Announce Strategic Alliance in Heart Failure
(01/05/2007)
Amgen Obtains Option on Cytokinetics' Drug Candidate CK-1827452
Cytokinetics Incorporated and Amgen announced a strategic collaboration to discover, develop and commercialize novel small-molecule therapeutics that activate cardiac muscle contractility for potential applications in the treatment of heart failure. ...
-
Galapagos expands and extends drug discovery collaboration with Amgen into 2008
(01/04/2007)
Galapagos NV announced that its service division BioFocus DPI has expanded and extended its longstanding drug discovery collaboration with Amgen through 2007 and 2008. BioFocus DPI will continue to provide biology, computational and medicinal ...
-
Amgen Names Yuji Orihara President, Amgen KK
(12/05/2006)
Amgen announced the appointment of Yuji Orihara to the position of president and representative director, Amgen KK, effective immediately. Amgen KK was formed in 1992 in Japan as a wholly owned subsidiary of Amgen Inc. Orihara will be responsible ...
-
Amgen Completes Acquisition of Avidia
(10/26/2006)
Amgen announced the completion of the acquisition of Avidia, a privately held biopharmaceutical company that discovers and develops a new class of human therapeutic known as Avimer(TM) proteins. The transaction provides Amgen with Avidia's lead ...
Additional information
Amgen Inc.
Thousand Oaks, CA, United States of America
Company
|
|
|
|
|
|
Top
